poseltinib (HM71224) / Hanmi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
poseltinib (HM71224) / Hanmi
RAjuvenate, NCT02628028 / 2015-003289-97: A Study of LY3337641 in Rheumatoid Arthritis

Terminated
2
286
Europe, Japan, US, RoW
LY3337641, Placebo
Eli Lilly and Company
Rheumatoid Arthritis
04/18
08/18
GPL study, NCT05335018: GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Recruiting
2
76
RoW
Glofitamab, Poseltinib, Lenalidomide
Seoul National University Hospital
Relapsed/Refractory Diffuse Large B Cell Lymphoma
11/25
11/26

Download Options